Sigyn Therapeutics Reports Q1 2025 Financial Results with Decreased Net Loss

Sigyn Therapeutics, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $668,564, a decrease from a loss of $758,088 in the same period of 2024. The company has not generated any revenue since its inception, and its total assets increased to $244.3 million as of March 31, 2025, up from $213.7 million at the end of 2024. The increase in assets was primarily driven by a rise in cash and other current assets, which totaled $68.1 million, compared to $21.2 million at the end of the previous year.

Operating expenses for the first quarter of 2025 decreased by 13.3% to $546,059, down from $629,972 in the prior year. This reduction was attributed to lower research and development costs, insurance expenses, and marketing costs, although there were increases in compensation and consulting fees. The company’s cash position at the end of the quarter was $12,895, reflecting a slight increase from $12,144 at the end of 2024. The company reported net cash used in operating activities of $294,446, compared to $235,612 in the same period last year.

In terms of strategic developments, Sigyn Therapeutics is advancing its lead product candidate, Sigyn Therapy™, which is designed to treat infectious disease disorders that are not addressable with existing drug therapies. The company is preparing for first-in-human clinical studies targeting end-stage renal disease patients with endotoxemia. Additionally, the company has initiated a Regulation D offering to raise funds through the sale of convertible debentures, with 69 units sold as of March 31, 2025, totaling $379,717.

The company’s liabilities also increased, totaling $5.2 million as of March 31, 2025, compared to $4.7 million at the end of 2024. This increase was primarily due to higher accounts payable and accrued payroll. Sigyn Therapeutics continues to face substantial doubt regarding its ability to continue as a going concern, as it has not yet generated revenue and has a significant accumulated deficit of $15.4 million. Management is actively seeking additional funding through public offerings or asset sales to support ongoing operations and development efforts.

Looking ahead, Sigyn Therapeutics aims to implement its business plan and generate revenue, although there are no assurances regarding the success of these efforts. The company is also focused on expanding its product pipeline, which includes technologies aimed at optimizing cancer therapies, such as the ImmunePrep™, ChemoPrep™, and ChemoPure™ platforms. The company’s future performance will depend on its ability to secure funding, advance its clinical studies, and ultimately achieve regulatory approvals for its therapeutic candidates.